Back to Agenda
The Use of Artificial Intelligence/ Machine Learning in Pharmacovigilance
Session Chair(s)
Phil Tregunno
Deputy Director - Patient Safety Monitoring
Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
Panel Session to enable discussion of critical issues in adoption of novel technology for pharmacovigilance, including input from opinion leaders from the US and EU from both regulators and industry
Learning Objective : Participants will gain insight into the regulatory and industry perspectives on technology adoption; where opportunities exist and how they might be leveraged under existing regulatory frameworks.
Speaker(s)
Leveraging Applied Artificial Intelligence Within Pharmacovigilance
Gerald Dal Pan, MD, MHS
FDA, United States
Director, Office of Surveillance and Epidemiology, CDER
AI in PV: An Industry and Research Perspective
Andrew Bate, PhD, MA
GlaxoSmithKline, United Kingdom
Vice President, Head of Safety Innovation and Analytics
AI in PV: An Industry Perspective
Kristof Huysentruyt, MSc
UCB Pharma S.A., Belgium
Head of Safety Data PROS
Have an account?